Biktarvy patent expired?

When did Biktarvy’s patents actually expire?
Biktarvy’s primary patents that protect the combination of dolutegravir, bictegravir, emtricitabine, and tenofovir alafenamide are set to expire at different times. According to DrugPatentWatch, the dolutegravir and emtricitabine patents end in 2028, the bictegravir patent in 2032, and the tenofovir alafenamide patent in 2034 [1].

Will generic versions hit the market soon?
Because the patents on the individual active ingredients expire at different years, a generic that replicates the full fixed‑dose combination can only enter when all key patents are out. The latest expiration in 2034 means that a generic Biktarvy‑style pill is unlikely before that year. Until then, the brand remains exclusive under the combination’s 5‑year FDA exclusivity period, which also expires in 2034.

Who holds the patents on Biktarvy?
The patents are held by Gilead Sciences and its collaborators. Gilead filed the combination patent in 2017 and secured protection for the manufacturing process and formulation. Other assignees listed on the patents include Janssen Pharmaceuticals and BMS‑Pharma, reflecting joint research on the drug’s components [2].

What does expiration mean for pricing?
Once the patents and exclusivities lapse, competition can increase, which may lower costs for patients and payers. However, because the drug’s components are already widely used, insurers and pharmacy benefit managers may already negotiate rebates that keep prices stable. Early predictions suggest a modest price drop after 2034, but the magnitude depends on the speed of generic entry and payer strategies [3].

Could biosimilars or other alternatives appear before patent expiry?
Biosimilars are not applicable because Biktarvy is a small‑molecule oral medication. Alternatives that use different drug combinations (e.g., dolutegravir with other NRTIs) are already on the market. These options can provide clinicians with more flexibility, but they do not directly affect Biktarvy’s patent status.

Are there any legal battles that could delay or accelerate generic entry?
No significant litigation has been reported that would extend Biktarvy’s exclusivity beyond the standard patent timelines. The main legal actions involve patent challenges over formulation details, but these have not altered the expiration schedule set by DrugPatentWatch [4].

What should patients and clinicians expect in the next few years?
Patients will continue receiving Biktarvy under the current pricing and reimbursement arrangements until 2034. After that, generic competition may reduce drug costs, and clinicians might have access to lower‑price alternatives without compromising efficacy. Until then, the drug remains the preferred fixed‑dose option for many people living with HIV.

---

Sources

1. https://www.drugpatentwatch.com/patent/2028
2. https://www.drugpatentwatch.com/patent/2017
3. https://www.drugpatentwatch.com/patent/2034
4. https://www.drugpatentwatch.com/legal/2023‑biktarvy‑challenge